Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open observational study of galantamine hydrobromide (Reminyl) administration for the treatment of patients with mild to moderate dementia of the Alzheimer type.

Next Previous
Trial Profile

Open observational study of galantamine hydrobromide (Reminyl) administration for the treatment of patients with mild to moderate dementia of the Alzheimer type.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Apr 2012

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Galantamine (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Sponsors Janssen-Cilag

Most Recent Events

  • 06 Oct 2009 Actual patient number (344) added as reported by ClinicalTrials.gov.
  • 19 Oct 2007 Status changed from in progress to completed.
  • 14 Oct 2006 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top